Addressing Misunderstandings in Applying HBV Treatment Guidelines

Download All
In this series of concise MedicalMinute presentations and accompanying downloadable slides, expert faculty interpet key guideline recommendations to address common misunderstandings in the management of patients with HBV infection.
Maria Buti, MD
Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA)
Francesco Negro, MD

EASL Guidelines

Here’s why it’s important to look for HDV coinfection in patients with HBV.

Francesco Negro, MD Released: July 7, 2021

The role of host factors in the monitoring and treatment of chronic hepatitis B is an area largely unexplored by the guidelines. Here’s my approach to assessing patients for treatment candidacy in the setting of other host factors.

Maria Buti, MD Released: August 26, 2021

This concise MedicalMinute presentation reviews the EASL recommendations for the individualizing treatment of HBV infection in persons at risk of renal or bone disease and pregnant women.

Francesco Negro, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 11, 2021 Expired: May 10, 2022

Hear expert insights on when to treat HBV: which factors to consider and how often to monitor them.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

In episode 4 of this ongoing series, listen to a conversation between Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, and his patient Mark, who presented with hepatitis B after receiving immunomodulatory treatment for rheumatoid arthritis.

Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA) Released: July 26, 2021

Review key data and EASL guideline recommendations on individualizing treatment for patients with HBV, including patients with renal or bone disease and pregnant women.

Francesco Negro, MD Released: May 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue